What Genomics does

Genomics plc is a UK-based TechBio company spun out of the University of Oxford in 2014 by four world-leading geneticists, including CEO Peter Donnelly and co-founder Gilean McVean. The company is headquartered in Oxford with a London flagship office, and operates with 101-250 employees. Its core technology is a proprietary genotype-phenotype database compiled from more than 45,000 genome-wide association studies (GWAS), which powers polygenic risk score-based disease prediction and, more recently, the Mystra AI platform for pharmaceutical drug target discovery and validation. The company describes this database as one of the largest in the world and uses it to claim that drug targets supported by human genetic evidence are 2.6 times more likely to succeed in clinical trials.

The company operates a multi-segment business model with subscription-recurring revenue across four primary customer groups. First, life sciences and pharmaceutical companies (Novo Nordisk, BioMarin, Vertex Pharmaceuticals, Biogen, Eisai, BridgeBio Pharma, Relation Therapeutics, and Greywolf Therapeutics) access the Mystra AI platform for drug target identification, biomarker discovery, and clinical trial optimization. Second, healthcare systems — notably the NHS in the UK, alongside a US-facing Health Insights USA product — deploy genomic risk prediction and stratification tools for precision health delivery. Third, insurance partners use polygenic risk scores for underwriting. Fourth, employers offer the platform as a workforce wellness benefit, and individual consumers can access at-home DNA testing via a self-serve website. Distribution runs through direct enterprise field sales for pharma and healthcare deals, and a self-serve digital platform for consumers, employers, and insurance.

Genomics is privately held and has raised approximately $135 million across multiple funding rounds, with the largest being a $44.6M Series 3 in January 2024 led by Foresite Capital and F-Prime Capital, alongside investors including Oxford Science Enterprises, IP Group, Lansdowne Partners, Vertex Pharmaceuticals, and Innovate UK. The company was recognized in the Sunday Times 100 Tech list and received endorsement from the UK Health Minister as a 'jewel in our crown' for national health innovation following the 2026 London flagship opening.

Name

Genomics

Legal name

Genomics Ltd.

Website

https://genomicsplc.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Genomics plc is an Oxford-based TechBio company that uses a proprietary database of 45,000+ GWAS studies and its Mystra AI platform to provide polygenic risk scores and drug target discovery services to pharmaceutical companies, healthcare systems including the NHS, insurers, employers, and individual consumers.

Ownership category

akta.pro rank

Product category

Genomic Data Analytics Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Population Genomics & Preventive Precision Health Programs (HLAAANAL), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA)

Keywords

• Genomic data platform
• Polygenic risk scores
• Drug target discovery
• Precision health analytics
• Human genetics AI

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Life Sciences / Pharma Partnerships: Revenue generated from partnerships with pharmaceutical companies for drug target discovery, biomarker identification, and clinical trial optimization using the company's genetic data platform and Mystra AI.
2. Healthcare and NHS Services: Revenue from precision health delivery through genomic risk prediction and stratification tools sold to healthcare systems and providers.
3. Insurance/Employer Wellness Programs: Revenue from predictive genomics services that transform underwriting for insurance partners and provide personalized health insights to employees for employer wellness programs.
4. Mystra AI Platform Licensing: Conversational AI platform licensed to pharmaceutical organizations to support drug target discovery and validation using human genetics data.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Genomics operates an AI-powered human genetics platform built on one of the world's largest genotype-phenotype databases (45,000+ GWAS) that delivers polygenic risk scores for absolute disease risk prediction and powers the Mystra AI conversational agentic platform for drug target discovery and validation. Its offerings span pharma/biotech drug discovery partnerships, healthcare system precision health delivery (e.g., NHS), insurance underwriting genomics, employer wellness programs, and at-home DNA testing for consumers.

Product overview

Genomics offers a unified platform centered on genetic risk prediction and the Mystra AI platform for drug discovery. The core Genomics Platform provides disease risk assessment through polygenic risk scores powered by one of the world's largest genetic databases. The portfolio includes specialized solutions for different market segments: Health Insights UK/USA for healthcare systems, Solutions for Partners (insurance underwriting), Solutions for Employers (workplace wellness), Solutions for Healthcare (precision medicine delivery), and Solutions for Life Sciences (pharma/biotech research). The Mystra AI platform, launched in 2025-2026, represents the company's AI-powered offering for pharmaceutical drug target discovery and validation using human genetics data.

Differentiator

Problem solved

Functional benefit

Brands

• Mystra: A conversational AI platform designed to accelerate drug target discovery and validation using large-scale human genetics data; launched as a separate brand with its own website at mystra.com

Products and services

• Genomics Platform The company's primary platform powered by one of the world's largest genetic databases, providing disease risk prediction through polygenic risk scores and DNA analysis for healthcare providers, insurers, employers, and life sciences companies.
• Mystra AI Platform A conversational agentic AI platform designed to accelerate drug target discovery and validation using large-scale human genetics data from the world's largest genotype-phenotype database, adopted by Novo Nordisk, BridgeBio Pharma, and Relation Therapeutics.
• Solutions for Life Sciences Pharmaceutical research solutions for drug discovery acceleration, clinical trial design optimization, biomarker identification, and post-market studies to help pharma and biotech companies deliver more targeted therapeutics.
• Solutions for Healthcare Genetic risk prediction and stratification tools enabling healthcare providers to deliver precision health from individuals to populations, including disease prevention and population health management.
• Health Insights UK Genomic risk prediction and stratification solution for the UK healthcare system enabling precision health delivery through polygenic risk scores.
• Health Insights USA Genomic health insights solution for the US market delivering precision health through genetic risk prediction and polygenic risk scores.
• Solutions for Partners Predictive genomics solutions for insurance partners, using advanced polygenic risk scores and data science to predict individual disease risk from a single at-home DNA test, transforming underwriting accuracy and policyholder engagement.
• Solutions for Employers Employee health engagement platform providing personalised health tools and guidance based on polygenic risk scores to improve employee wellbeing and quality of life.

Quantifiable outcome

• Drug targets supported by human genetic evidence are 2.6x more likely to succeed in clinical trials
• +2 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Greywolf TherapeuticscoreStrategic or Co-development Partner · 29 April 2026Genomics entered a strategic partnership with clinical-stage biotech Greywolf Therapeutics to analyze large-scale genetic datasets evaluating how ERAP (Endoplasmic Reticulum Aminopeptidase) enzyme variants influence autoimmune disease risk across multiple conditions. The insights guide Greywolf's indication selection and pipeline development, including its Phase 1/2 trial for axial spondyloarthritis and expansion into inflammatory bowel disease and psoriasis. The collaboration leverages Genomics' proprietary genotype-phenotype data resource.
• BioMarin Pharmaceutical Inc.coreStrategic or Co-development PartnerGenomics and BioMarin collaborated on research analyzing global biobank data for three ultra-rare lysosomal storage disorders (MPS IVA, MPS VI, and CLN2 disease). The research identified geographic regions with high underdiagnosis rates to support earlier genetic diagnosis and expand treatment access. This was presented at the ACMG Clinical Genetics Meeting 2026.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Tempus Labs: AI-powered precision medicine platform integrating clinical and molecular data for oncology and beyond. Comparable as a broader incumbent selling AI/data infrastructure into pharma and providers.
• Illumina: Dominant DNA sequencing technology and instruments provider with growing downstream informatics and population genomics initiatives. Relevant incumbent across the genomics stack that Genomics sits upon.

Direct peers

• deCODE genetics: Amgen-owned human genetics research company that pioneered population-scale genotype-phenotype research for drug target discovery. Closely comparable to Genomics' core data asset and pharma business model.
• Regeneron Genetics Center: Large-scale human genetics platform within Regeneron, sequencing hundreds of thousands of exomes to power drug discovery. Directly comparable in mission and use of population genetics for pharma R&D.
• Insitro: AI/ML-driven drug discovery company combining machine learning with biology to identify novel targets and predict therapeutic outcomes. Comparable to Genomics' Mystra AI positioning for pharma target discovery.
• Recursion Pharmaceuticals: TechBio company combining high-throughput biology, automation, and AI to discover new medicines at scale. Competes with Genomics for pharma AI-drug-discovery budgets and partnerships.
• BenevolentAI: UK-based AI drug discovery company applying machine learning to biomedical knowledge graphs for target identification. A direct peer in AI-enabled pharma target discovery, with geographic overlap.

Emerging players

• Owkin: AI-for-health company building federated learning models on patient data for drug discovery and precision medicine. Overlaps with Genomics on pharma AI partnerships and translational data strategy.
• Human Longevity Inc. Precision health platform combining whole-genome sequencing, AI, and clinical data for disease risk prediction. Comparable to Genomics' polygenic risk score and precision health offering for consumers and providers.
• 23andMe: Consumer genetic testing company with a therapeutics arm leveraging genetic data for drug discovery. Overlaps with Genomics on consumer polygenic health and pharma genetic-evidence licensing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/genomicsplc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds8 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genomics